Alpha 2.0
Login Register
» Articles » PMID: 26459538

Determination of MICs of Levofloxacin for Mycobacterium Tuberculosis with GyrA Mutations

Overview
Journal Int J Tuberc Lung Dis
Specialty Pulmonary Medicine
Date 2015 Oct 14
PMID 26459538
Citations 7
Authors
P Kambli
K Ajbani
C Nikam
A Khillari
A Shetty
Z Udwadia
S B Georghiou
T C Rodwell
A Catanzaro
C Rodrigues
Affiliations
Soon will be listed here.
Abstract

The purpose of the present study was to correlate gyrA mutations found in Mycobacterium tuberculosis isolates using the GenoType(®) MTBDRsl assay with minimum inhibitory concentrations of the fluoroquinolone levofloxacin (LVX). Of 123 archived clinical M. tuberculosis isolates evaluated, 93 isolates had an Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly or His mutation and 30 were wild-type. Phenotypically, gyrA mutations Ala90Val, Ser91Pro or Asp94Ala showed a low level of resistance to LVX, while Asp94Asn/Tyr, Asp94Gly or Asp94His mutations had high-level resistance.

Citing Articles

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now.

Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M Cureus. 2023; 15(2):e35154.

PMID: 36819973 PMC: 9938784. DOI: 10.7759/cureus.35154.

Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs Among by a Reverse Dot Blot Hybridization Assay.

Li G, Guo Q, Liu H, Wan L, Jiang Y, Li M Infect Drug Resist. 2020; 13:4091-4104.

PMID: 33204126 PMC: 7666996. DOI: 10.2147/IDR.S270209.

Drug-Resistant Tuberculosis, Lebanon, 2016 - 2017.

El Achkar S, Demanche C, Osman M, Rafei R, Ismail M, Yaacoub H Emerg Infect Dis. 2019; 25(3):564-568.

PMID: 30789124 PMC: 6390733. DOI: 10.3201/eid2503.181375.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya J, Mpagama S, Bendet P, Srivastava S, Koeuth T Clin Infect Dis. 2018; 67(suppl_3):S293-S302.

PMID: 30496461 PMC: 6260169. DOI: 10.1093/cid/ciy611.

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Heyckendorf J, Andres S, Koser C, Olaru I, Schon T, Sturegard E Antimicrob Agents Chemother. 2017; 62(2).

PMID: 29133554 PMC: 5786814. DOI: 10.1128/AAC.01550-17.

References
1.
Lin S, Desmond E, Bonato D, Gross W, Siddiqi S . Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol. 2009; 47(11):3630-4. PMC: 2772628. DOI: 10.1128/JCM.00803-09. View
2.
Xu P, Li X, Zhao M, Gui X, DeRiemer K, Gagneux S . Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother. 2009; 53(7):3170-2. PMC: 2704692. DOI: 10.1128/AAC.00177-09. View
3.
Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z . Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis (Edinb). 2014; 95(2):137-41. PMC: 4361297. DOI: 10.1016/j.tube.2014.11.003. View
4.
Yin X, Yu Z . Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect. 2010; 61(2):150-4. DOI: 10.1016/j.jinf.2010.05.001. View
5.
Ginsburg A, Grosset J, Bishai W . Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003; 3(7):432-42. DOI: 10.1016/s1473-3099(03)00671-6. View